Adalimumab

An anti-TNF biologic medicine that you inject yourself at home, for moderate to severe Crohn's disease and ulcerative colitis.

Last updated 17 November 2026 · 4 min read

On this page
  1. What is it and how does it work?
  2. What is it used for?
  3. Before you start
  4. How is it taken?
  5. Drug levels and antibodies
  6. Side effects
  7. Long-term risks
  8. Vaccinations
  9. Pregnancy and breastfeeding
  10. Surgery, dental work and travel
  11. If adalimumab does not work

Adalimumab is a biologic medicine used for Crohn's disease (CD) and ulcerative colitis (UC). Because it comes as an injection pen you use at home, many people find it fits easily around work and family life.

What is it and how does it work?

Adalimumab is an antibody, made in the laboratory, that blocks tumour necrosis factor (TNF), a chemical messenger that drives inflammation in inflammatory bowel disease (IBD). It works in the same way as infliximab, and both are called anti-TNFs.

The original brand is Humira. Most people in the UK now have a biosimilar, such as Amgevita, Imraldi, Hyrimoz, Yuflyma, Idacio or Hulio. Biosimilars work just as well and are as safe, and they cost the NHS much less. The pens differ slightly between brands, so if you are switched, ask for a demonstration of the new one.

What is it used for?

  • Moderate to severe CD or UC that hasn't responded to, or can't be treated with, steroids and immunosuppressants such as azathioprine.
  • Crohn's disease with fistulas.
  • Children and teenagers with Crohn's disease, as well as adults.

It is sometimes combined with azathioprine or methotrexate to help it work for longer.

Before you start

As with other anti-TNFs, you will be checked for tuberculosis (TB), hepatitis B and C, HIV and immunity to chickenpox, because adalimumab could make these infections worse. Tell your team if you have heart failure, multiple sclerosis or another nerve condition, or have had cancer. Get any live vaccines you need before starting.

How is it taken?

Adalimumab is injected under the skin of the tummy or thigh with a pre-filled pen or syringe. An IBD nurse will show you how, and most people quickly find it straightforward.

  • Starting doses: usually 160 mg at the first dose, then 80 mg two weeks later.
  • Then: 40 mg every two weeks.

If it isn't working well enough, your team may increase the dose, for example to every week. The pens are delivered to your home by a homecare company. Keep them in the fridge; most brands can be kept at room temperature for a limited time (check the leaflet for your brand), which helps when travelling.

Some people feel better within a couple of weeks; for others it takes up to three months.

Tips for injecting: take the pen out of the fridge 15 to 30 minutes before, to make the injection more comfortable; change the injection site each time; and don't inject into skin that is bruised, red or hard.

Drug levels and antibodies

Your team may measure the level of adalimumab in your blood and check for antibodies against it, to decide whether the dose needs changing or a different medicine would work better.

Side effects

Most people have no serious side effects.

Common:

  • Injection-site reactions: redness, itching, pain or swelling where you inject, which usually settle within a few days.
  • Headache, rash and minor infections such as colds and sinus infections.

Important:

  • Infections. Adalimumab reduces your ability to fight some infections, and serious infections, including TB, can occur. Contact your team or GP promptly if you have a fever, feel unwell or have signs of an infection, and tell them you take adalimumab. Your team may advise missing a dose while you are unwell.
  • Skin problems, including a psoriasis-like rash, which can usually be treated.
  • Abnormal liver tests, found on routine blood tests.

Rarely: worsening of heart failure; inflammation of the nerves, causing numbness, tingling, weakness or vision problems; a lupus-like illness; and allergic reactions.

Long-term risks

As with infliximab, there is a small increase in the risk of some skin cancers (use sunscreen, avoid sunbeds and have new or changing patches of skin checked) and of lymphoma, mainly when combined with azathioprine or mercaptopurine. The risk remains low. See IBD, risk of bowel cancer and lymphoma.

Vaccinations

Don't have live vaccines while taking adalimumab, or for at least three months after stopping, unless your specialist advises otherwise. These include yellow fever, oral typhoid and MMR. Non-live vaccines are safe and recommended, including the yearly flu injection, COVID-19, pneumococcal and the non-live shingles vaccine.

If you have never had chickenpox and you come into contact with someone who has chickenpox or shingles, contact your GP or IBD team the same day.

Pregnancy and breastfeeding

Adalimumab is not thought to harm an unborn baby, and most specialists advise continuing it during pregnancy, as a flare-up is a greater risk to mother and baby. Your team may adjust the timing of doses late in pregnancy. Because adalimumab crosses the placenta, tell the baby's GP and health visitor: some live vaccines, such as BCG and rotavirus, may need to be delayed. Adalimumab is considered compatible with breastfeeding.

If you are planning a pregnancy, talk to your IBD team first; see Pregnancy and Inflammatory Bowel Disease.

Surgery, dental work and travel

Tell your surgeon or dentist that you take adalimumab before any operation or procedure; you may be asked to miss a dose. When travelling, carry your pens in your hand luggage in a cool bag, with a letter from your IBD team. See Travel Insurance with Crohn's or Colitis.

If adalimumab does not work

Your team may increase the dose, add an immunosuppressant, or switch you to another medicine, such as infliximab, vedolizumab, ustekinumab or a newer treatment such as risankizumab or upadacitinib. See Medicines for Crohn's Disease and Ulcerative Colitis.

Never stop adalimumab without discussing it with your IBD team first.